Cipher Pharmaceuticals Past Earnings Performance
Past criteria checks 1/6
Cipher Pharmaceuticals has been growing earnings at an average annual rate of 28.4%, while the Pharmaceuticals industry saw earnings growing at 39% annually. Revenues have been growing at an average rate of 6.5% per year. Cipher Pharmaceuticals's return on equity is 8.8%, and it has net margins of 23.4%.
Key information
28.4%
Earnings growth rate
29.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 6.5% |
| Return on equity | 8.8% |
| Net Margin | 23.4% |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable
May 09
Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?
Apr 28
Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence
Feb 23 Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt
Dec 13Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think
Nov 14With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For
Nov 12Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 09There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise
Mar 23Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)
Mar 22Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock
May 14Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)
May 18Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next
Mar 20Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12%
Jan 26
Revenue & Expenses Breakdown
How Cipher Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 40 | 9 | 16 | 0 |
| 31 Dec 24 | 33 | 12 | 12 | 0 |
| 30 Sep 24 | 26 | 16 | 9 | 0 |
| 30 Jun 24 | 22 | 23 | 6 | 0 |
| 31 Mar 24 | 22 | 23 | 6 | 0 |
| 31 Dec 23 | 21 | 20 | 5 | 0 |
| 30 Sep 23 | 21 | 32 | 5 | 0 |
| 30 Jun 23 | 20 | 28 | 5 | 0 |
| 31 Mar 23 | 20 | 27 | 5 | 0 |
| 31 Dec 22 | 21 | 27 | 5 | 0 |
| 30 Sep 22 | 22 | 10 | 5 | 0 |
| 30 Jun 22 | 21 | 8 | 5 | 0 |
| 31 Mar 22 | 22 | 9 | 5 | 0 |
| 31 Dec 21 | 22 | 8 | 5 | 0 |
| 30 Sep 21 | 22 | 5 | 6 | 0 |
| 30 Jun 21 | 23 | 6 | 6 | 0 |
| 31 Mar 21 | 21 | 3 | 6 | 0 |
| 31 Dec 20 | 22 | 4 | 6 | 0 |
| 30 Sep 20 | 21 | 7 | 6 | 0 |
| 30 Jun 20 | 22 | 3 | 5 | 0 |
| 31 Mar 20 | 23 | 4 | 6 | 0 |
| 31 Dec 19 | 22 | 3 | 8 | 0 |
| 30 Sep 19 | 23 | -1 | 11 | 0 |
| 30 Jun 19 | 22 | 2 | 13 | 0 |
| 31 Mar 19 | 23 | 3 | 14 | 1 |
| 31 Dec 18 | 23 | 1 | 14 | 1 |
| 30 Sep 18 | 28 | 6 | 13 | 1 |
| 30 Jun 18 | 34 | 9 | 13 | 0 |
| 31 Mar 18 | 37 | 11 | 13 | 0 |
| 31 Dec 17 | 40 | 11 | 13 | 0 |
| 30 Sep 17 | 34 | 7 | 13 | 0 |
| 30 Jun 17 | 32 | 5 | 13 | 0 |
| 31 Mar 17 | 31 | 1 | 14 | 1 |
| 31 Dec 16 | 30 | 4 | 16 | 1 |
| 30 Sep 16 | 33 | 6 | 23 | 1 |
| 30 Jun 16 | 34 | 2 | 28 | 0 |
| 31 Mar 16 | 34 | 1 | 29 | 0 |
| 31 Dec 15 | 34 | 2 | 29 | 1 |
| 30 Sep 15 | 32 | 3 | 21 | 1 |
| 30 Jun 15 | 30 | 13 | 14 | 1 |
| 31 Mar 15 | 30 | 18 | 10 | 1 |
| 31 Dec 14 | 29 | 19 | 9 | 1 |
| 30 Sep 14 | 33 | 31 | 7 | 1 |
| 30 Jun 14 | 32 | 27 | 7 | 1 |
Quality Earnings: CPH has a high level of non-cash earnings.
Growing Profit Margin: CPH's current net profit margins (23.4%) are lower than last year .
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CPH's earnings have grown significantly by 28.4% per year over the past 5 years.
Accelerating Growth: CPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CPH had negative earnings growth (-59.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-45%).
Return on Equity
High ROE: CPH's Return on Equity (8.8%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 08:16 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cipher Pharmaceuticals Inc. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Loe | Byron Capital Markets |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |